Angewandte Chemie · 2018 · 17 citations · 51 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyChemotherapyMolecular OncologyColorectal CancerLigand BindingOrganometallic Anticancer AgentsPlatinum CompoundsPlatinum-based AgentsSelectivityTumor Suppressor Gene MutationsTumor Suppressor P53
Abstract The ligands L 1 and L 2 both form separable dinuclear double‐stranded helicate and mesocate complexes with Ru II . In contrast to clinically approved platinates, the helicate isomer of [Ru 2 ( L 1 ) 2 ] 4+ was preferentially cytotoxic to isogenic cells (HCT116 p53 −/− ), which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity, with the achiral isomer being preferentially cytotoxic towards HCT116 p53 +/+ . Other structurally similar Ru II ‐containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be “tuned” to either genotype. In the search for compounds that can target difficult‐to‐treat tumours that lack the p53 tumour suppressor gene, [Ru 2 ( L 1 ) 2 ] 4+ is a promising compound for further development.
51
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Scott W. Lowe, H. Earl Ruley, Tyler Jacks et al. · Cell · 1993 · 2.9K citations
Brian H. Robinson, Eric W. Kaler · Current Opinion in Colloid & Interface Science · 1999 · 1.8K citations
<i>p53</i> Status and the Efficacy of Cancer Therapy in Vivo
Scott W. Lowe, Stephan Bodis, Andrea I. McClatchey et al. · Science · 1994 · 1.5K citations
Medicine, Cancer Biology, Oncology +17
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
Fred Bunz, Paul M. Hwang, Chris Torrance et al. · Journal of Clinical Investigation · 1999 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Vincenzo Balzani · Pure and Applied Chemistry · 1990 · 851 citations · Full text